EQS-News

Formycon invites to the conference call on the results of the financial year 2023 and announces participation in international investor conferences in the 2nd quarter of 2024 - Seite 2

Equity Forum Spring Conference 2024
Dr. Stefan Glombitza (CEO)
Frankfurt
 

May 15 – 17, 2024
Hauck Aufhäuser Stockpicker Summit
Enno Spillner (CFO)
Kitzbühel
 

May 21 – 23, 2024
Berenberg European Conference
Enno Spillner (CFO)
New York City
 

June 3, 2024
mwb Research Roundtable
Dr. Stefan Glombitza (CEO), Enno Spillner (CFO), Nicola Mikulcik (CBO), Dr. Andreas Seidl (CSO)
Virtual
 

June 5 – 6, 2024
Jefferies Global Healthcare Conference NYC
Enno Spillner (CFO)
New York City
 

June 6 – 7, 2024
Warburg Highlights
Dr. Stefan Glombitza (CEO)
Hamburg
 

Please find our current Events at:
https://www.formycon.com/en/investor-relations/calendar/

 

About Formycon:
Formycon AG (FSE: FYB) is a leading, independent developer of high-quality biosimilars, follow-on products of biopharmaceutical medicines. The company focuses on therapies in ophthalmology, immunology, immuno-oncology and other key disease areas, covering almost the entire value chain from technical development through clinical trials to approval by the regulatory authorities. For commercialization of its biosimilars, Formycon relies on strong, well-trusted and long-term partnerships worldwide. With FYB201/Ranibizumab, Formycon already has a biosimilar on the market in Europe and the USA. Another five biosimilar candidates are currently in development. With its biosimilars, Formycon is making an important contribution to providing as many patients as possible with access to highly effective and affordable medicines. Formycon AG is headquartered in Munich and is listed on the Frankfurt Stock Exchange: FYB / ISIN: DE000A1EWVY8 / WKN: A1EWVY. Further information can be found at: https://www.formycon.com/